Thalia Field

Dr. Thalia Field is an Associate Professor in the Division of Neurology at the University of British Columbia and holds the Sauder Family/Heart and Stroke Foundation Professorship of Stroke Research. She is a clinician-researcher specializing in stroke neurology, with a focus on clinical trials and stroke in younger adults, particularly cerebral venous thrombosis (CVT) and congenital heart disease. Her research includes leading the SECRET trial on CVT treatment strategies and a national longitudinal study on brain health in congenital heart disease patients. She has been principal investigator on multiple high-impact studies, including the ESCAPE-NA1 trial evaluating NA-1 in stroke and the TEMPO-2 trial on tenecteplase for minor ischemic stroke.

Her research interests span anticoagulation protocols, stroke prevention, neuroimaging advancements, and healthcare equity in stroke care. Awards include the 2025 Innovation and Translational Research Award and the 2020 Excellence in Patient-Oriented Research Award. Dr. Field actively contributes to clinical guidelines, including the Canadian Stroke Best Practice Recommendations and American Heart Association scientific statements on cerebral venous thrombosis and cervical artery dissection.

Key ongoing projects include the ACTION-CVT study on direct oral anticoagulants and the STOP-CAD study on antithrombotic therapies for cervical artery dissection. Her work emphasizes translational research bridging clinical practice and population health, with a focus on improving outcomes for underserved stroke populations.